Latest Period
Q1 2026
Security Snapshot
Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share (RLAY) Institutional Ownership
CUSIP: 75943R102
13F Institutional Holders and Ownership History from Q3 2020 to Q2 2026
Institutions Reporting
241
Shares (Excl. Options)
183,654,386
Price
$9.95
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- RLAY on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 183,654,386
- Total 13F value
- $1,826,833,241
- Portfolio coverage rank
- 0%
- Share change
- +9,415,160
- Value change
- +$121,908,026
- Number of holders
- 241
- Shares outstanding
- 4,389,099
- SEC-reported price per share
- $18.73
- Insider filing price
- $18.73
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RLAY - Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 75943R102.
- 241 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 241 to 38 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,826,833,241 to $75,122,400.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 241 institutions filings for Q1 2026.
Security key
75943R102
Latest holder period
Q1 2026
13F holders
241
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
RLAY full holder history
Relay Therapeutics, Inc. SEC filings
Relay Therapeutics, Inc. company facts
Relay Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 75943R102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
RLAY
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | +26% | $88,740,000 | +$19,053,000 | 17,000,000 | +27% | Commodore Capital LP | 30 Sep 2025 |
| Casdin Capital, LLC | 7.5% | $110,010,236 | 13,003,574 | CASDIN CAPITAL, LLC | 31 Dec 2025 | |||
| BlackRock, Inc. | 6.1% | -30% | $32,882,558 | -$13,928,338 | 10,308,012 | -30% | BlackRock, Inc. | 31 Mar 2025 |
| PERCEPTIVE ADVISORS LLC | 10% | +94% | $4,362,830 | -$89,215,124 | 438,471 | -95% | Perceptive Advisors LLC | 06 Apr 2026 |
As of 31 Mar 2026, 241 institutional investors reported holding 183,654,386 shares of Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share (RLAY). This represents 4184% of the company’s total 4,389,099 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
3400%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD | 636% | 27,904,963 | 0% | 3.6% | $277,654,382 |
| Commodore Capital LP | 387% | 17,000,000 | 0% | 9.8% | $169,150,000 |
| Casdin Capital, LLC | 329% | 14,418,574 | +11% | 11% | $143,464,811 |
| BlackRock, Inc. | 296% | 12,975,299 | -1.9% | 0% | $129,104,225 |
| PERCEPTIVE ADVISORS LLC | 222% | 9,751,141 | +412% | 1.9% | $97,023,853 |
| Bellevue Group AG | 178% | 7,795,242 | -6.6% | 1.8% | $77,562,658 |
| VANGUARD CAPITAL MANAGEMENT LLC | 168% | 7,387,465 | 0% | 0% | $73,505,277 |
| STATE STREET CORP | 142% | 6,233,545 | -3% | 0% | $62,023,773 |
| Nextech Invest, Ltd. | 126% | 5,526,506 | +18% | 3.9% | $54,988,735 |
| TCG Crossover Management, LLC | 97% | 4,273,356 | +33% | 1.2% | $42,519,892 |
| FMR LLC | 84% | 3,695,431 | +2178% | 0% | $36,769,536 |
| GEODE CAPITAL MANAGEMENT, LLC | 80% | 3,510,636 | +3% | 0% | $34,938,159 |
| Balyasny Asset Management L.P. | 69% | 3,039,179 | +45% | 0.06% | $30,239,831 |
| Spruce Street Capital LP | 68% | 2,984,125 | 0% | 7.1% | $29,692,044 |
| DIMENSIONAL FUND ADVISORS LP | 67% | 2,940,536 | +19% | 0.01% | $29,248,486 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 59% | 2,590,000 | +418% | 0.04% | $25,770,500 |
| GOLDMAN SACHS GROUP INC | 58% | 2,541,861 | +37% | 0% | $25,291,517 |
| MPM BIOIMPACT LLC | 54% | 2,359,586 | +5.7% | 1.8% | $23,477,881 |
| BANK OF AMERICA CORP /DE/ | 44% | 1,937,695 | +86% | 0% | $19,280,066 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 44% | 1,924,938 | +17% | 0% | $19,154,000 |
| EcoR1 Capital, LLC | 43% | 1,904,762 | 0.81% | $18,952,382 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 42% | 1,863,565 | 0% | 0% | $18,542,472 |
| NORTHERN TRUST CORP | 38% | 1,675,387 | +47% | 0% | $16,670,101 |
| Alphabet Inc. | 36% | 1,564,173 | -0.29% | 0.39% | $15,563,521 |
| MORGAN STANLEY | 33% | 1,432,003 | -29% | 0% | $14,248,431 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
24
Latest
Q1 2026
Rows shown
1-24 of 24
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 3,991,033 | $75,122,400 | +$50,974,953 | $18.71 | 38 |
| 2026 Q1 | 183,654,386 | $1,826,833,241 | +$121,908,026 | $9.95 | 241 |
| 2025 Q4 | 173,567,140 | $1,468,277,175 | +$55,238,266 | $8.46 | 226 |
| 2025 Q3 | 166,100,415 | $866,877,590 | -$18,449,389 | $5.22 | 195 |
| 2025 Q2 | 170,927,354 | $591,366,333 | +$36,190,035 | $3.46 | 203 |
| 2025 Q1 | 162,665,545 | $426,190,863 | -$16,276,230 | $2.62 | 205 |
| 2024 Q4 | 163,889,986 | $675,297,060 | -$42,360,167 | $4.12 | 197 |
| 2024 Q3 | 163,415,012 | $1,156,675,796 | +$253,277,512 | $7.08 | 193 |
| 2024 Q2 | 126,697,163 | $826,050,230 | -$42,426,305 | $6.52 | 171 |
| 2024 Q1 | 132,236,260 | $1,097,561,545 | +$24,572,655 | $8.30 | 182 |
| 2023 Q4 | 127,244,702 | $1,400,985,578 | -$17,110,979 | $11.01 | 176 |
| 2023 Q3 | 130,456,510 | $1,097,122,997 | -$2,918,566 | $8.41 | 169 |
| 2023 Q2 | 129,294,786 | $1,623,964,520 | -$20,848,790 | $12.56 | 159 |
| 2023 Q1 | 131,039,866 | $2,156,444,291 | +$53,163,179 | $16.47 | 155 |
| 2022 Q4 | 128,192,171 | $1,915,159,649 | +$58,936,160 | $14.94 | 163 |
| 2022 Q3 | 123,551,085 | $2,763,964,560 | +$25,518,843 | $22.37 | 153 |
| 2022 Q2 | 120,596,011 | $2,019,993,086 | +$124,571,798 | $16.75 | 137 |
| 2022 Q1 | 113,095,261 | $3,384,210,971 | +$67,735,824 | $29.93 | 133 |
| 2021 Q4 | 110,982,949 | $3,407,692,692 | +$588,792,014 | $30.71 | 128 |
| 2021 Q3 | 91,778,622 | $2,894,965,132 | +$74,331,777 | $31.53 | 132 |
| 2021 Q2 | 89,144,608 | $3,261,742,353 | +$138,052,473 | $36.59 | 124 |
| 2021 Q1 | 85,493,244 | $2,955,555,198 | -$171,240,328 | $34.57 | 135 |
| 2020 Q4 | 87,701,562 | $3,644,892,889 | +$108,159,345 | $41.56 | 115 |
| 2020 Q3 | 84,683,348 | $3,603,495,710 | +$3,603,495,710 | $42.59 | 94 |